ADBE vs MRK: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Adobe Inc. · Technology
$248.16
+45.0% upside to fair value
High Conviction
Grade B
VS
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
MRK |
| Current Price |
$248.16 |
$114.27 |
| Fair Value Estimate |
$359.82 |
$118.00 |
| Upside to Fair Value |
+45.0%
|
+3.3%
|
| Market Cap |
$101.2B |
$282.2B |
| Forward P/E |
14.1x
|
22.4x
|
| EV / EBITDA |
—
|
13.5x
|
| Price / Sales |
4.1x
|
4.3x
|
| Price / FCF |
9.8x
|
20.2x
|
| Revenue Growth YoY |
+3.3%
|
+5.0%
|
| Gross Margin |
89.1%
|
81.9%
|
| Operating Margin |
36.6%
|
27.5%
|
| Return on Equity |
62.3%
|
5.6%
|
| Dividend Yield |
— |
2.91% |
| FCF Yield |
10.2%
|
4.95%
|
| Analyst Consensus |
Hold
|
Overweight
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Accumulation Zones
| Metric |
ADBE |
MRK |
| Zone Low |
$269.87 |
$88.50 |
| Zone High |
$305.85 |
$100.30 |
| In Buy Zone? |
Yes
|
No
|